Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04395196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor 2 versions Re-verified since Mar 25, 2025, no change to tracked fieldsv14-v15
  2. Minor Primary completion date: Aug 1, 2027 to Oct 15, 2027
    • Study completion date: Mar 30, 2028 to May 15, 2028
    v13
  3. Notable Trial status: Not Yet Recruiting to Recruitingv12
  4. Minor Secondary endpoints: 3 to 2v11
  5. Notable Primary completion date: Feb 1, 2027 to Aug 1, 2027
    • Start date: Oct 1, 2022 to Apr 13, 2023
    • Study completion date: Sep 30, 2027 to Mar 30, 2028
    • Eligibility criteria expanded, about 5 words
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Primary completion date: Dec 1, 2027 to Feb 1, 2027
    • Study completion date: Sep 30, 2028 to Sep 30, 2027
    v9
  2. Minor Primary completion date: Oct 1, 2027 to Dec 1, 2027
    • Study completion date: Oct 1, 2027 to Sep 30, 2028
    v8
  3. Notable Start date: Jul 1, 2022 to Oct 1, 2022
    • Primary and study completion dates: Jul 1, 2027 to Oct 1, 2027
    v7
  4. Notable Phase: Phase 2/3 to Phase 2
    • Start date: Mar 15, 2022 to Jul 1, 2022
    • Primary and study completion dates: Mar 15, 2027 to Jul 1, 2027
    v6
  5. Minor Re-verified, no change to tracked fieldsv5
  6. Notable Primary and study completion dates: Feb 1, 2026 to Mar 15, 2027
    • Start date: Feb 1, 2021 to Mar 15, 2022
    v4
  7. Minor Re-verified, no change to tracked fieldsv3
  8. Minor Secondary endpoints revised (3)v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Although the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitigate effects of PAE on growth and development. Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. In an R21 feasibility trial, 70 heavy drinkers were randomly assigned to receive a daily dose of 2g of choline or a placebo from initiation of antenatal care to delivery in Cape Town, South Africa, where the incidence of heavy drinking during pregnancy and fetal alcohol syndrome are among the highest in the world. When compared with infants in the placebo arm, infants in the choline-treated arm were more likely to meet criterion for eyeblink conditioning, demonstrated markedly better recognition memory on the Fagan Test of Infant Intelligence, which is known to have predictive validity for school-age IQ, and had better postnatal gains in weight and head circumference. Key features of this study included the higher choline dose (4.4 times adequate intake (AI), compared to 1.7-2.5 in previous human studies) and initiation of treatment early in pregnancy. We are now conducting a fully-powered, double-blind, randomized, placebo-controlled choline supplementation trial in heavy drinking pregnant women from a rural community in South Africa (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed; (3) to use innovative methods in causal inference analysis to examine protocol adherence as an important source of variation in treatment efficacy and to identify sociodemographic factors associated with non-compliance in order to facilitate implementation of the intervention protocol in clinical settings; and (4) in exploratory analyses, to examine whether maternal choline supplementation is particularly effective in women with lower dietary choline intake or poor nutritional status.
Trial Details
NCT Number NCT04395196
Lead Sponsor Wayne State University
Collaborators: University of Cape Town, Columbia University
Conditions
(from sponsor)
Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome
Related terms Fetal Alcohol Spectrum Disorders
Enrollment 288 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov